Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,877 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Mobile, AlabamaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT05363319Recruiting
Cemiplimab study in adults with advanced lung cancer
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
Klagenfurt, CarinthiaAges 18 years+ - NCT06562920RecruitingPhase 2
Immunotherapy plus chemo and SBRT before surgery for limited-stage small cell lung cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
Hangzhou, ZhejiangAges 18–75 - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Los Angeles, CaliforniaAges 18 years+ - NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT06647836Enrolling by invitation
Immunotherapy for advanced lung squamous cancer
This trial tests how well immunotherapy works as a first treatment for advanced lung squamous cell carcinoma, either alone or with chemotherapy. It aims to see if this approach can help patients who haven't had prior cancer treatment.
Wuhan, HubeiAges 18–80 - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Los Angeles, CaliforniaAges 18 years+ - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT01639508RecruitingPhase 2
Cabozantinib for lung cancer with specific gene changes
This trial studies how well cabozantinib works in advanced lung cancer when the tumor has certain gene changes (like RET, ROS1, NTRK, MET, or AXL). It may help slow tumor growth after standard treatments, depending on your tumor test results.
Basking Ridge, New JerseyAges 18 years+ - NCT06165419RecruitingPhase 2
High-dose radiation for spine metastases from solid tumors
This trial tests a new way of giving high-dose radiation to solid tumors that have spread to the spine. It is for people whose spine is stable, have not had prior treatment to that area, and have only minor weakness (if any).
Stony Brook, New YorkAges 18 years+ - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT05358548RecruitingPhase 2
Alternating treatment for advanced lung and head-neck cancers
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Elizabeth, New JerseyAges 18 years+ - NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07232420RecruitingPhase 1
Study of BL-M24D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M24D1, for people with advanced non-small cell lung cancer or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06576635Recruiting
Chemotherapy study for advanced lung cancer
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
Chicago, IllinoisAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT07001618RecruitingPhase 2
Fecal transplant with immunotherapy for advanced lung cancer
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
DijonAges 18 years+ - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT06931717RecruitingPhase 3
Immunotherapy after lung cancer surgery for those not getting chemo
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
ViennaAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,877 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.